The emergence of dual-action receptor agonists in the approach of type 2 diabetes and obesity has sparked considerable attention, particularly regarding retatrutide and tirzepatide. While both medications target both https://teganjrft034697.therainblog.com/37508768/retatrutide-vs-tirzepatide-a-comparative-analysis